New FAQs address Stage 2 transitions of care measure

The Centers for Medicare & Medicaid Services and the Office of the National Coordinator of Health IT have jointly released two new FAQs that help explain requirements for the transitions of care measure for Meaningful Use Stage 2.

The measure's objective is:

The eligible professional (EP), eligible hospital or critical-access hospital (CAH) who transitions their patient to another setting of care or provider of care or refers their patient to another provider of care should provide summary care record for each transition of care or referral.

The FAQs focus on the certification criteria for this measure, as well as more detailed information about the objective. The questions are:

  • What certification approaches would satisfy the 2014 edition transitions of care certification criteria adopted at 45 CFR 170.314(b)(1) and (b)(2) as well as permit an eligible provider to have EHR technology that meets the Certified EHR Technology (CEHRT) definition? Please emphasize how the adopted transport standards fit in. Read the answer here.
  • For Meaningful Use Stage 2's transitions of care and referrals objective, in what ways can I meet the second measure that requires more than 10 percent of the summary care records I provide for transitions of care and referrals to be electronically transmitted? Read the answer here.
Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.